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Objective: To observe the role and mechanism of CO-
releasing molecule (CORM)-2 in lung injury induced by is-
chemia-reperfusion (IR) of hind limbs in rats.
Methods: A rat model of lung injury induced by IR of
hind limbs was established. A total of 40 Sprague Dawley
(SD) rats were randomly divided into 5 groups (n = 8): sham,
sham + CORM-2, IR, IR+ CORM-2andIR+dimethyl sulfox-
ide (DMSO). Rats in the IR group received hind limb is-
chemia for 2 hours and reperfusion for 2 hours, rats in the
sham group underwent sham surgerywithout infrarenal aorta
occlusion, rats in the IR+CORM-2 group and in the sham +
CORM-2 group were given CORM-2 (10 µmol/kg intrave-
nous bolus) 5 minutes before reperfusion or at the corre-
sponding time points, while rats in the IR + DMSO group
was treated with the same dose of vehicle (DMSO) at the
same time. The lung tissue structure, polymorphonuclear
neutrophil (PMN) count, wet-to-dry weight ratio (W/D),
malondialdehyde (MDA) content, myeloperoxidase (MPO)
activity, intercellular adhesion molecule-1 (ICAM-1)
expression,degradation and nuclear factor (NF)-B
activity in the lungs were assessed.
Results: As compared with the sham group, lung PMNs
number, W/D, MDA content, MPO activity, ICAM-1 ex-
pression and NF-B activity significantly increased in the
IR group, but the level ofdecresed (P<0.01). Com-
pared with the IR group, lung PMNs number, W/D, MDA
content, MPO activity and ICAM-1 expression significantly
decreased in the IR+COMR-2 group (P<0.01), while the level
of increased.
Conclusions: These data demonstrate that CORM-2
attenuates limb IR-induced lung injury through inhibiting
ICAM-1 protein expression, NF-B pathway and the leu-
kocytes sequestration in the lungs following limb IR in rats,
suggesting that CORM-2 may be used as a therapeutic
agent against lung injury induced by limb IR.
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Limb ischemia is a common clinical event. Al-though reperfusion of ischemic limb is essentialin alleviating the ischemic injury, reperfusion of
ischemia tissues is associated with acute lung injury.1
Limb ischemia-reperfusion (IR) is now recognized as
one form of acute inflammations in whichactivated poly-
morphonuclear neutrophil (PMN) and reactive oxygen
species play a key role.2 Carbon monoxide (CO) gas is
now well recognized as a key modulator of the cellular
response to inflammation and oxidative stress.3,4 Un-
der such pathological conditions, CO production is in-
creased endogenously in conjunction with biliverdin and
bilirubin following up-regulation of heme oxygenase-1
(HO-1), a stress inducible enzyme responsible for the
degradation of heme.5 The induction of the HO-1 sys-
tem is regarded as a valuable intracellular defense
against the generation of reactive oxygen species and
the ensuing oxidant-mediated injury.6 Interestingly, CO
gas has been shown to reduce the inflammatory re-
sponse in a similar fashion to HO-1.3-5 Such a protec-
tive effect appears to be ubiquitous in nature as it has
been demonstrated in a variety of experimental models
of diseases relating to the cardiovascular and immune
systems as well as in several cell types including en-
dothelial and cardiac cells, hepatocytes, and
macrophages.7 In view of the increasing evidence sup-
porting a beneficial roleof CO in a variety of pathophysi-
ological conditions, much interest has been focused on
the actions of this molecule for therapeuticpurposes.
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Recently, Motterlini andhis colleagues8 reported that
transition metal carbonyls are good candidatesfor CO
carriers as CO-releasing molecules (CORMs) function
in biological bodies. CORM-2, one of the novel group of
CORMs, is a dimer of tricarboxylic dichlororuthenium
(II), alipid-soluble molecule that is found to release CO
in vitro and in vivo and reproducesthe effects of HO-1-
derived CO in cardio-protective actions.9Inour previous
studies, we had investigated the effects of HO/CO on
the lung injuries induced by limb IR in rats. We found
that limb IR upregulated the lung HO-1 mRNA, protein
expression, and CO levels, which attenuated the fol-
lowing lung injury.10,11 The effects of CORM-2 on the
lung injury induced by limb IR have not been fully
understood. The purpose of the present study was to
identify whether pharmacological intervention with
CORM-2 could attenuate the remote lung injury in limb
IR model. Our hypothesis is that CORM-2 plays a pro-
tective role in lung injury induced by limb IR and the
mechanisms are associated with the reduction of ICAM-1
expression, NF-B activity, and PMN sequestration.
METHODS
Animal model12 and experimental protocols
A total of 40 healthy male Sprague Dawley (SD)
rats [weighing 250-300 g, 4 to 6 (average 5.2) months
of age, provided by the Department of Experimental
Zoology, Hebei University, Shijiazhuang, China] were
anesthetized with intraperitoneal administration of so-
dium pentobarbital (40 mg/kg body weight) and fixed in
a supine position on a heated restraining board at 37°C
after being shaved on the abdomen. The right external
jugular vein was cannulated for drug administration and
the left carotid artery was cannulated for arterial blood
pressure monitoring. All the animals were then allowed
a 30-minute equilibration period. A laparotomy was per-
formed via amidline abdominal incision anda microvas-
cular clip was placed across the abdominal aorta and
immediately distal to the renal vessels for 2 hours. Then
the clip was removed and reperfusion was allowed for 2
hours.
The rats were randomly divided into 5 groups (n=8
in each group): sham, sham+CORM-2, IR, IR+CORM-2
and IR+ dimethyl sulfoxide (DMSO). The surgical sham
group underwent full surgical preparation including iso-
lation of the infrarenal aorta without occlusion. The IR
group received 2 hours of ischemia and 2 hours of
reperfusion. Rats in the IR+CORM-2 group were given
CORM-2 (10 µmol/kg intravenous bolus) 5 minutes
before reperfusion and 145 minutes for the rats in the
sham+CORM-2group, while rats in the IR+DMSO group
were treated with the same volume of vehicle (0.5%
DMSO diluted by 0.9% saline) at the same time. All
the rats were killed after the indicated periods of
reperfusion, and lung tissues and blood samples were
taken for furtheranalysis.Tricarboxylicdichlororuthenium
(II) dimer (CORM-2) was obtained from Sigma Aldrich
(St. Louis, USA) and solubilized in DMSO to obtain a
10-mmol/L stock. The concentration of CORM-2 used
in the present study was based on a previous report of
the use of this compound in rats.9
Lung histopathological examination and polymor-
phonuclear (PMN) count
The right middle lobe of lung was harvested and
fixed in 10% formalin. After embedded in paraffin, sec-
tions of 8 µm were stained with hematoxylin and eosin
(HE) for light microscopic observation. All microscopic
sections were examined in a blind fashion by a
pathologist. Lung PMN sequestration was quantitated
through counting alveolar septal wall PMNs. PMN en-
trapment was expressed as the mean number of PMNs
per 10 high-power fields (HPF, ×1000).
Myeloperoxidase (MPO) assay
The right lower lobe of lung was homogenized in 50
mmol/L potassium phosphate buffer (PB, pH 6.0) and
centrifugedat 10000×g for 10 minutes. The pellets were
suspended in 50 mmol/L PB containing 0.5%
hexadecyltrimethylammonium bromide. After three
cycles of freezing and thawing (with sonication between
cycles), the samples were centrifuged at 10 000 ×g for
10 minutes. Aliquots (0.3 ml) were added to 2.3 ml of
reactionmixture containing50 mmol/LPB, o-dianisidine,
and 20 mmol/L H2O2 solution. The MPO activity was
measured using MPO assay kit (Nanjing Jiancheng
Corporation, China) and expressed as U/g tissues.
Assessment of lung malondialdehyde (MDA) con-
tent
The right upper lobe of lung was harvested and im-
mediately homogenized on ice in 9 volumes of saline.
The homogenates were centrifuged at 3 000 ×g at 4°C
for 10 minutes. The MDA content in the supernatant was
measured using MDA assay kit (Nanjing Jiancheng
Corporation, China).
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Lung edema
The extent of lung edema was measured by tissue
wet-to-dry weight ratios (W/D). At the end of each
experiment, the left lung lobes were harvested, weighed
immediately (wet weight) and then allowed to dry for 72
hours at 90°C in a vacuum oven. The lungs were then
reweighed and the W/D was calculated.
Protein extraction and Western blotting
Theright lung lobeswere homogenized in lysisbuffer
[50mmol/L hydroxyethyl piperazine ethanesulfonic acid
(HEPES), 5 mmol/L ethylenediamine tetraacetic acid
(EDTA), 50 mmol/L NaCl and 1%Triton X-100, pH 7.5]
containing phenylmethyl sulfonylfluoride (PMSF).
Samples were kept on ice for 1 hour and then centri-
fuged (4°C) at 12 000×g for 30 minutes. After
precipitation, unsolubilized fraction was discarded and
the protein concentration in the supernatant was deter-
mined by Coomassie Blue dye-binding assay (Nanjing
Jiancheng Corporation, China). Aliquots (30 µg) of pro-
teins from each sample were electrophoresed on a 12%
sodium dodecyl sulfate (SDS)-polyacrylamide gel for 4
hours at 100 V. The protein samples were transferred
ontoanitrocellulosemembrane (Amersham,USA).Non-
specific antibody binding was blocked by 3% nonfat
dried milk in phosphate buffered saline (PBS, pH 7.4) for
2 hours at room temperature. The membrane was then
probed with polyclonal rabbit anti-rat intercellular adhe-
sion molecule-1 (ICAM-1, Santa Cruz Biotechnology,
USA) at a concentration of 1:1000 in Tris-buffered sa-
line containing0.1%Tween-20 (TBST) overnight at 4°C.
After 3 washes with TBST, blots were visualized with
the use of an amplified horseradish peroxidase (HRP)
kit (Wuhan Boshide Corporation, China). The presence
of ICAM-1 was indicated by the development of a brown
color.
Analysis of NF-B DNA binding activity
Nuclear extracts of lung tissues were prepared with
the method described by Deryckere and Gannon12.
Double-strandedNF-B consensus oligonucleotide (5'-
AGTGAGGGGACTTTCCCAGGC-3',Promega,Madison,
Wisconsin, USA) was end-labeled with [ -32P] ATP (3
000 Ci/mmol at 10 mCi/ml, Amersham, Arlington
Heights, USA). Binding reactions containing equal
amounts of proteins (20 µg) and 35 fmol (about 50 000
counts/min)of oligonucleotidewereperformedfor30 min-
utes in binding buffer [4% glycerol, 1 mmol/LMgCl2, 0.5
mmol/L EDTA, pH 8.0, 0.5 mmol/L dithiothreitol,
50 mmol/L NaCl,10 mmol/L Tris, pH 7.6, and 50 µg/ml
poly (dI-dC)]. Reaction volumes were held constant to
15 µl. Reaction productswere separated in a 4% poly-
acrylamide gel and analyzed byautoradiography.
Immunohistochemical analysis of  degra-
dation
Sections of 8 µm-thickness lung tissues were treated
by 0.3% H2O2 in methanol to block endogenous peroxide
activities. Immunohistochemical stainingwasperformed
using rabbit antibody against rat(Santa Cruz
Biotechnology, USA) at 1:100 dilution and streptavidin/
peroxidase (SP) immunohistochemicalassay kit (Zymed,
USA). The positive signal was indicated by the develop-
ment of a brown color.
Statistical analysis
The values were expressed as ± s. The data were
analyzed by unpaired t test. Differences were consid-
ered as statistical significance at P<0.05.
RESULTS
Effects of CORM-2 on lung injury following limb IR
Lung edema, hemorrhage and leukocyte aggrega-
tion were observed in the lungs after 2 hours of ischemia
and 2 hours of reperfusion in hind limbs of rats. The lung
MDA content and W/D increased significantly in the IR
group when compared with the sham controls (P<0.01).
Compared with the IR group, the above-described
changes significantly decreased in the IR +CORM-2
group (P<0.01) and the lung injury was attenuated as
determined by light microscopic examination. There
were no measurable differences between the sham+
CORM-2 group and the sham group and between the
IR group and the IR +DMSO group (P>0.05, Table 1).
Effects of CORM-2 on lung PMN recruitment fol-
lowing limb IR
The lung PMN count and MPO level increased sig-
nificantly in the IR group when compared with the sham
controls (P<0.01). However,comparedwith theIRgroup,
the lung PMN count and MPO level significantly de-
creased in the IR +CORM-2 group (P<0.01). There were
no measurable differences between the sham+ CORM-2
group and the sham group and between the IR group
and the IR +DMSO group (P>0.05, Table1).
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Effects of CORM-2 on lung ICAM-1 expression fol-
lowing limb IR
There was a little ICAM-1 expression in the sham
lung tissuesdetermined byWesternblotting (Fig.1, Lane1).
The expression of ICAM-1 in the IR group significantly in-
Effects of CORM-2 on lungdegradation fol-
lowing limb IR
I%highly expressed in the control lung tissues,
which was reflected by immunostaining (Fig.2). Com-
pared with the controls, the immunoactivity of
wassignificnatly reducedby limbIR treatment. However,
administration of CORM-2 in vivo significantly reversed
the effects of IR and increased the level of(Fig.2).
Therefore, degradation of  in the lungs caused
by limb IR determined by immunohistochemistry was
significantly inhibited by CORM-2 treatment.
Effects of CORM-2 on lung NF-B activation fol-
lowing limb IR
Binding activities of nuclear proteins to the radiola-
beled consensus binding sequences of NF-B were
assessed by electrophoretic mobility shift assay
(EMSA). No significant binding activity was detected in
the sham and sham+CORM-2 groups, suggesting that
CORM-2 alone had no ability to activate NF-B path-
way (Fig.3, Lanes 1 and 2). NF-B activation in the
lungs increased markedly following limb IR and this
activity was inhibited by in vivo administrationof CORM-2
(Fig.3, Lanes 3 and 4).
creased compared with the sham controls (Fig.1, Lane 2).
With the in vivo administration of CORM-2, ICAM-1 ex-
pression significantly decreased (Fig.1, Lane 3). Fig.1,
Lane 4 shows that DMSO does not attenuate the ex-
pression of ICAM-1 resulted from limb IR.
Fig.1. Effects of CORM-2 on ICAM-1 expression in the lungs after
limb IR assayed by Western blotting. 1: Sham group; 2: IR group; 3:
IR + CORM-2 group; 4: IR + DMSO group.
1 2 3   4
Fig.2. Immunohistochemical analysis for the effects of CORM-2 on degradation in the lungs after limb IR (×400). A:Sham group;
B:IR group; C:IR+ CORM-2 group.
Table 1. Effects of CORM-2 on lung PMN count, MDA content, MPO activity and W/D following limb IR  ( ± s , n=8)
Groups PMN/10HPF   t MDA (nmol/L/g) t W/D t MPO (U/g)   t
7.29 ± 0.58
6.93 ± 0.40
20.34 ± 2.08*
12.44 ± 2.17#
20.83 ± 2.77
Sham
Sham+ CORM-2
IR
IR + CORM-2
IR+DMSO
17.63 ± 2.88
17.75 ± 4.06
61.38 ± 5.15*
35.89 ± 5.22#
60.13 ± 3.68
121.15 ± 4.80
122.19 ± 4.35
207.58 ± 11.70*
147.21 ± 16.14#
208.14 ± 16.53
3.28 ± 0.36
3.12 ± 0.22
5.25 ± 0.32*
3.35 ± 0.29#
5.04 ± 0.33
*P<0.01, compared with the control group; #P<0.01, compared with the IR group.
 _
–0.0194
28.026
15.896
0.125
 _
0.199
32.162
14.607
0.054
 _
0.116
33.965
40.757
0.294
 _
0.290
11.195
3.497
0.163
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DISCUSSION
Upon reperfusion of an ischemic hind limb, a sys-
temic inflammatory response occurs. Acute lung injury
after hind-limb or lower torso IR has been documented
in both clinical and experimental settings1,2 and is con-
firmed in this study. Our previous studies have impli-
cated that endogenous CO and exogenous CO (250
ppm) have protective effects on the lungs from the in-
jury of limb IR in rats.10,11,14 In this study, we investi-
gated the effects of CORM-2 on this kind of lung injury.
As a new CORM, CORM-2 has been demonstrated to
have the ability to release CO in biological systems8,9
and have anti-inflammatory actions by the liberated CO
in an in vitro model of lipopolysaccharide (LPS)-stimu-
lated macrophages15. The results of this study showed
that CORM-2 significantly attenuated lung edema,
hemorrhage, leucocyte aggregation and oxidant lung
injury invivo, while treatment with DMSO could not pro-
tect the lungs from limb IR-induced injury. Because
CORM-2wasgiven just before releaseof infrarenal aorta
occlusion, it benefited the lungs through alleviating the
components of tissue injury, which was associatedwith
reperfusion, as opposed to the injury inflicted by is-
chemiaitself.
Though the exact mechanism is still unknown, pre-
vious studies have suggested that neutrophil activation,
sequestration and their subsequent infiltration in the
lungs play a key role in the development of hind limb
IR-related lung injury.1, 2 Activatedneutrophils can cause
tissue damage by releasing oxidantsand proteases.16
Tissue MPO activity is frequently used to estimate PMN
accumulation in inflamed tissues and correlates sig-
nificantly with the number and the activation of PMN in
tissues.16 In the present study, we measured neutro-
phil accumulation both by determining MPO concen-
tration within the lungs and histopathological counting.
We found that lung MPO activity and lung PMN num-
ber level increased markedly after lower torso IR and in
vivo administration of CORM-2 signif icant ly
downregulated both MPO activity and PMN number.
MDA, an end product of lipidperoxidation, is an indica-
tor of free radical generation and the oxidant injury. We
found that CORM-2significantly reversed the increased
MDA level in the lungs following limb IR. These data
indicated that CORM-2 effectively prevented PMN
chemotaxis and infiltration in the lungs after hind limb
IR, subsequently decreased the production of oxidants,
and reduced tissue oxidative injury. The direct cause of
leukocyte aggregation after IR injury is considered to
be the higher expression of adhesion molecules,1,2 and
one of the most important of them is ICAM-1. It has
been demonstrated that the ICAM-1 expression in-
creases in the lungs following limb IR and the antibody
to ICAM-1 shows protective effects through reducing
the recruitment of neutrophils in the lungs.1 The results
of this study showed that the expression of ICAM-1 in
the lungs was markedly up-regulated 2 hours after IR.
Administration of CORM-2 was able to inhibit the
upregulation of ICAM-1 induced by IR injury. The re-
sults suggested that CORM-2 might inhibit leukocyte
aggregation and adhesion, and consequently decrease
inflammatory responses effectively in the lungs induced
by limb IR.
The molecular mechanisms underlying CO-induced
protection remain to be elucidated. It is reported that
CO modulates many different signaling pathways that
could potentially lead to tissue protection.3 One plau-
sible pathway that may potentially mediate CO donor-
induced protection is the NF-B signaling pathway.
NF-B is a transcription factor controlling gene ex-
pressionduringinflammation, immunity,cellproliferation,
stress response, and apoptosis.17 It can be activated
by many agents includingcytokines, viral infection, ul-
traviolet (UV) ray radiation, and free radicals. In
unstimulated cells, NF-B is sequestered in the cyto-
plasm by tightly binding with its inhibitory factor,.
Upon activation, thesubunit is rapidly phosphory-
lated and degraded, allowing NF-B to translocateinto
the nucleus and activate target genes. The gene ex-
pressionof theproinflammatorymediators,includingTNF-
and ICAM-1, is controlled at least in part by the transcrip-
tion factor nuclear factor-B (NF-B).17,18 Inhibition of
NF-B can attenuate the lung reperfusion injury.19 We
Fig.3. EMSA analysis of effects of CORM-2-mediated NF-B ac-
tivation on limb IR-induced lungs.1:Sham group; 2: Sham + CORM-
2 group; 3:IR group; 4:IR + CORM-2 group.
1 2 3   4
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studied NF-B pathway through assayingdeg-
radation and nuclear NF-B DNA-binding activity in
the lungs. The results of the degradation of I%and
the increased DNA binding activity of NF-B in the
lungs induced by limb IR suggested the translocation
of NF-B into nuclei, therefore turning on NF-B
downstream genes, such as ICAM-1, and leading to
lung injury. However, administration of CORM-2, but
not DMSO, in vivo blocked the activation of NF-B
pathway, which was demonstrated by reduced I%
degradation and NF-B activation. These data sug-
gested that the protection of CORM-2 was related to
the inhibition of NF-B signaling pathway.
In conclusion, the current studies found that sys-
tematic administration of CORM-2 could improve lung
injury through reducing oxidant stress and leukocyte
sequestration and inhibiting the expression of ICAM-1
and NF-B pathway. Our study suggests that CORM-
2 may be used as a therapeuticagent for the lung injury
caused by limb surgery or hemorrhagic shock.
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